drugset / Trial / NCT03770052

Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie

NCT03770052

RandomizedParallel-groupDouble-blindTreatment

Summary

Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie

Timeline

Start
2018-10-24
Primary completion
2021-08-19
Completion
2021-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobeglitazone Small molecule 0.25 mg
Subject Lobeglitazone Small molecule 0.5 mg